Life Sciences Blog

Leading drug provider stresses need for consistency in biosimilar naming

Posted on October 23rd, by Michael Shapiro-Barr

Hospira, Inc., a leading drug provider, stressed the need for biosimilar drugs to given the same nonproprietary names as their original biologics, for safe prescribing and patient access.  Hospira’s senior vice president and chief scientific officer brought up this need at the recent World Health Organization Consultation on International Nonproprietary Names.  Hospira stressed that consistency in naming will avoid confusion and improve tracking.

Read More



Comments are closed.

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Media Quotes

  • Mercedes Meyer, a patent lawyer with the firm Drinker Biddle in Washington, D.C., said the Supreme Court’s failure to provide “bright-line guidance”—a ruling that would settle once-and-for all whether patent settlements are legal or not—means there’s “really no difference now than what was going on.” Mercedes Meyer
    CNBC: High Court Allows FTC to Challenge 'Pay-to-Delay' Generics

From the Blog

The Debate Over Mobile Health Software Regulation

On November 19th, the House Energy and Commerce Subcommittee on Health held a hearing to examine the federal regulation of mobile medical applications (mobile...

23 Skidoo – Genomes, Gamesmanship and the First Amendment

On November 22, 2013, the Inquisition collided with the Internet.  On that date, the Food and Drug Administration issued a Warning Letter threatening 23andMe,...

FDA’s Warning Letter to 23andMe: Ethical and Legal Issues

The FDA’s warning letter to 23andMe, the maker of mail-order genetic tests, highlights the challenging legal and ethical issues posed by such products.  While...